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Abstract—Oxidative stress induced by superoxide is implicated in hypertension. NADPH oxidase is the main source of
superoxide in phagocytic and vascular cells, and the p22phox subunit is involved in NADPH oxidase activation. Recently
we reported an association of930A/G polymorphism in the human p22phox gene promoter with hypertension. This study
was designed to investigate the functional role of this polymorphism in hypertension. We thus investigated the
relationships between the 930A/G polymorphism and p22phox expression and NADPH oxidase–mediated superoxide
production in phagocytic cells from 70 patients with essential hypertension and 70 normotensive controls. Genotyping
of the polymorphism was performed by restriction fragment length polymorphism. NADPH oxidase activity was
determined by chemiluminescence assays, and p22phox mRNA and protein expression was measured by Northern and
Western blotting, respectively. Compared with hypertensive subjects with the AA/AG genotype, hypertensive subjects
with the GG genotype exhibited increased (P0.05) phagocytic p22phox mRNA (1.260.06 arbitrary unit [AU] versus
0.990.03 AU) and protein levels (0.580.05 AU versus 0.340.04 AU) and enhanced NADPH oxidase activity
(1998181 counts/s versus 1322112 counts/s). No differences in these parameters were observed among genotypes
in normotensive cells. Transfection experiments on vascular smooth muscle cells showed that the A-to-G substitution
of this polymorphism produced an increased reporter gene expression in hypertensive cells. Nitric oxide production, as
assessed by measurement of serum nitric oxide metabolites, was lower in GG hypertensive subjects than in AA/AG
hypertensive subjects. In conclusion, these results suggest that hypertensive subjects carrying the GG genotype of the
p22phox 930A/G polymorphism are highly exposed to NADPH oxidase-mediated oxidative stress. (Hypertension. 2004;
44:163-169.)
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Oxidative stress induced by reactive oxygen species(ROS), including superoxide (O2), is increased in
arterial hypertension,1 and it has been proposed as a possible
mechanism that predisposes to development of atherosclero-
sis in hypertension.2 Among other effects, oxidative stress
may account for the decrease in the bioavailability of nitric
oxide (NO), because it reacts with O2.3 NO has been shown
to regulate vascular tone and to inhibit platelet aggregation,
thrombus formation, leukocyte adhesion, and vascular
proliferation.4
A plasma membrane-associated NADPH oxidase is present
in endothelial cells, vascular smooth muscle cells (VSMCs),
and fibroblasts and seems to be the most important source of
O2 in the vessel wall.5–7 A major component of NADPH
oxidase is the p22phox protein, a critical subunit that plays an
essential role in NADPH oxidase activation in vascular cells.8
Enhanced vascular NADPH oxidase activity has been shown
to be associated with upregulation of p22phox mRNA in several
models of hypertension, including the spontaneously hyper-
tensive rat (SHR).9–11 Moreover, increased ROS generation
has been found to be associated with augmented vascular
NADPH oxidase activity in VSMCs from peripheral arteries
in patients with hypertension.12
The human p22phox gene has several allelic variants,13,14
some of which are associated with cardiovascular disease. We
recently reported the existence of functional polymorphisms
in the p22phox gene promoter in SHR.15 In addition, we have
described a novel genetic variation in the human p22phox gene
promoter, the 930A/G polymorphism, associated with essen-
tial hypertension.16 We have hypothesized that the G allele of
the 930A/G polymorphism could be associated with higher
p22phox expression and NADPH oxidase activity in patients
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with essential hypertension. Because NADPH oxidase pres-
ent in phagocytes, including the p22phox subunit, is structurally
very similar to vascular NADPH oxidase,1 the studies re-
ported here were performed in these cells. NO metabolites
were determined in serum samples of the same subjects to
evaluate the potential impact of O2 production on systemic
generation of NO.17 Furthermore, promoter activity assays
were performed in cultured VSMCs obtained from SHR and
normotensive Wistar-Kyoto (WKY) rats to address the po-
tential importance of the hypertensive stimulus on the func-
tional activation of this polymorphism.
Methods
An expanded Methods section is available in the online supplement
at http://www.hypertensionaha.org.
Subjects
The study was performed in individuals who were referred to our
institution for routine medical examination. The hypertensive group
comprised 70 subjects with systolic blood pressure 139 mm Hg,
diastolic blood pressure 89 mm Hg, or both. Half of the patients
were receiving antihypertensive treatment when they enrolled in the
study. As a control group, 70 normotensive subjects were also
studied. Clinical screenings were based on medical history, physical
examination, and routine analytical tests. According to institutional
guidelines, subjects were aware of the research nature of the study
and agreed to participate. The study was carried out in accordance
with the Helsinki Declaration, and the Ethical Committee of the
University Clinic of Navarra approved the protocol.
Preparation of Phagocytic Cells
Mononuclear phagocytic cells were isolated from blood samples
with Lymphoprep.
NADPH Oxidase Activity
Phagocytic cells (400 000 cells) were incubated (37°C for 30
minutes) in basal conditions and with phorbol myristate acetate
(PMA; 3.2106 mol/L), a protein kinase C (PKC) activator; O2
production was measured using lucigenin (105 mol/L). Chemilumi-
nescence was determined every 10 seconds for 5 minutes in a
Berthold luminometer. The area under the curve was used to quantify
chemiluminescence. Data are expressed as counts per second. In
previous experiments, basal and PMA-stimulated O2 production
was completely abolished with apocynin (2.5103 mol/L), a
specific intracellular inhibitor of NADPH oxidase. Specificity of the
lucigenin for O2 was verified because the addition of the O2
scavenger superoxide dismutase (SOD; 1000 U/mL) abolished the
signal.
The lucigenin-based assay was validated against an independent
measurement of O2 production using SOD-inhibitable ferricyto-
chrome C reduction that closely correlated with lucigenin measure-
ments (n5; r0.92, P0.001).
NO Metabolites in Serum
Serum samples were obtained after overnight fasting to measure
nitrate and nitrite (NO2/NO3, NOx).18 NOx concentration was
evaluated using a colorimetric assay based on Griess reaction.
p22phox Expression
p22phox mRNA expression was determined by Northern blotting and
by quantitative real-time reverse transcription–polymerase chain
reaction. Western blotting with a mouse anti-p22phox antibody (kindly
provided by Professor D. Roos, University of Amsterdam, The
Netherlands) was used to evaluate p22phox protein abundance.
Genotyping of the 930A/G Polymorphism of
p22phox Gene
The A-to-G substitution at position930 in the p22phox promoter was
typed by restriction fragment length polymorphism as previously
described.16
Directed Mutagenesis
Transient reporter gene expression assays with chimeric constructs
containing A (c1-A) or G (c1-G) allelic p22phox gene promoter and
luciferase gene were performed as previously reported.15,16 Trans-
fections were performed on VSMCs from the cell line A7r5 and on
VSMCs obtained from SHR and WKY rats. In some experiments, we
performed cotransfection of allelic constructs with the CCAAT
enhancer-binding protein (C/EBP)  plasmid, generously provided
by Professor S.L. McKnight (University of Texas Southwestern
Medical Center, Dallas, Tex).
Statistical Analysis
Data are expressed as meanSEM. Statistical significance of differ-
ences in O2 generation, p22phox expression, and NOx levels among
groups was assessed by 1-way ANOVA. A Scheffe´ post hoc test was
used to examine differences between groups when significance was
achieved. Differences in the luciferase activity between allelic
variants were assessed by Student t test.
Results
Clinical Characteristics of the Subjects Studied
The demographic and clinical characteristics of normotensive
and hypertensive subjects are shown in Table 1. Hypertensive
subjects exhibited significantly higher values of age, body
mass index, and blood pressure than normotensive subjects.
Each subject was genotyped for the 930A/G polymor-
phism. To enhance statistical power, and given the low allelic
frequency of the A allele, AA homozygote subjects were
added to AG heterozygous subjects. Thus, homogeneous
normotensive and hypertensive groups were composed of 35
subjects with GG genotype and 35 subjects with AA/AG
genotype (10 individuals AA and 25 individuals AG).
Relation Between the 930A/G Polymorphism and
Phagocytic NADPH Oxidase Activity and
p22phox Expression
Although baseline NADPH oxidase activity was similar in
hypertensive and normotensive groups (16721 counts/s
versus 14817 counts/s, PNS), PMA-stimulated NADPH
oxidase activity was higher in hypertensive than in normo-
tensive subjects (1660129 counts/s versus 1125109
counts/s, P0.01). Whereas baseline NADPH oxidase activ-
ity was similar in hypertensive subjects with AA/AG and GG
genotype (16822 counts/s versus 16631 counts/s,
PNS), PMA-stimulated NADPH oxidase activity was
higher in GG than in AA/AG hypertensive subjects
(1998181 counts/s versus 1322112 counts/s, P0.05)
(Figure 1). No differences in NADPH oxidase activity were
observed between AG and AA hypertensive subjects (data
not shown). Finally, no differences in PMA-stimulated
NADPH oxidase activity were found between AA/AG and
GG genotypes in normotensive subjects (1092108 counts/s
versus 1158149 counts/s, PNS).
p22phox mRNA levels were higher in GG than in AA/AG
hypertensive subjects (1.260.06 AU versus 0.990.03 AU,
P0.05) (Figure 2). No differences in p22phox expression were
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found between AG and AA hypertensive subjects (data not
shown). No differences in p22phox expression were found
between AA/AG and GG normotensive subjects
(1.000.03 AU versus 1.010.05 AU, PNS). These
Northern blot data were confirmed by quantitative real-
time polymerase chain reaction. In fact, whereas increased
p22phox mRNA levels were observed in GG hypertensive
subjects compared with AA/AG hypertensive subjects
(1.340.06 AU versus 1.000.04 AU, P0.05), no dif-
ferences were found between GG and AA/AG normoten-
sive subjects (0.940.03 AU versus 1.000.04 AU,
PNS).
p22phox protein abundance was higher in hypertensive than
in normotensive subjects (0.460.03 AU versus 0.250.02
AU, P0.01); p22phox protein expression was higher in GG
than in AA/AG hypertensive subjects (0.580.05 AU versus
0.340.04 AU, P0.05) (Figure 2). No differences in p22phox
protein expression were found between AA/AG and GG
normotensive subjects (0.260.03 AU versus 0.240.04
AU, PNS).
The differences in p22phox expression and NADPH oxidase
activity between the 2 hypertensive subgroups were not
related to age, gender, body mass index, blood pressure, and
metabolic factors because these potentially confounding fac-
tors were similar in the 2 subgroups (Table 2). In addition, no
differences were found in the frequency of antihypertensive
drugs and other cardiovascular medication (eg, statins) be-
tween the 2 hypertensive subgroups.
Interaction of the 930A/G Polymorphism With
Cell Phenotype
To investigate whether the A-to-G substitution may influence
gene expression depending on cell phenotype, transfection
experiments were carried out on the cell line A7r5 and on
VSMCs obtained from WKY and SHR rats, which possess a
characteristic normotensive and hypertensive phenotype, re-
spectively.15 As shown in Figure 3A, the A-to-G substitution
increased the reporter gene expression by 30% in hyperten-
sive cells. This allelic change did not modify the reporter
gene expression in normotensive cells and in A7r5 cells
(Figure 3B and 3C).
Because the 930 polymorphic site lies on a potential
binding site for C/EBP transcription factors, additional ex-
periments were carried out on A7r5 cells. Cotransfection of
p22phox allelic constructs with C/EBP increased the p22phox
promoter activity (Figure 4A). This effect was significantly
TABLE 1. Clinical Characteristics of Normotensive and Hypertensive Subjects
Parameter Normotensives Hypertensives P
Gender, male/female 56/14 58/12 NS
Age, years 561 601 0.05
Body mass index, kg/m2 27.80.7 29.30.7 0.05
Smokers, n (%) 26 (37) 21 (30) NS
Diabetics, n (%) 9 (13) 8 (11) NS
Systolic blood pressure, mm Hg 1212 1492 0.05
Diastolic blood pressure, mm Hg 781 911 0.05
Mean arterial pressure, mm Hg 932 1101 0.05
Pulse pressure, mm Hg 431 572 0.05
Glucose, mg/dL 1003 1033 NS
Total cholesterol, mg/dL 2247 2335 NS
HDL-cholesterol, mg/dL 482 512 NS
LDL-cholesterol, mg/dL 1555 1603 NS
Triglycerides, mg/dL 1086 1116 NS
Granulocytes, cells/mm3 4099181 4300195 NS
Lymphocytes, cells/mm3 196091 185396 NS
Monocytes, cells/mm3 30223 31821 NS
NS indicates not significant.
Figure 1. Effect of the 930A/G polymorphism genotype on
NADPH oxidase activity. O2 production was determined by
lucigenin chemiluminescence after PMA stimulation in phago-
cytic cells from 70 normotensive subjects and 70 hypertensive
subjects. Bars show meanSEM. *P0.05 compared with
AA/AG hypertensive subjects and with AA/AG and GG normo-
tensive subjects.
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higher on the promoter activity of the G than of the A allelic
construct. These results were associated with upregulated
C/EBP protein expression, which was nearly absent in
C/EBP-nontransfected control A7r5 cells (Figure 4B).
Association of the 930A/G Polymorphism With
NO Production
NOx levels were lower in hypertensive than in normotensive
subjects (4.80.2 mol/L versus 6.20.3 mol/L, P0.05). In
Figure 2. Effect of the 930A/G polymor-
phism genotype on p22phox expression.
A, Expression of phagocytic p22phox
mRNA was adjusted for the expression
of the housekeeping gene GAPDH. B,
p22phox mRNA expression was estimated
in samples from 70 normotensive sub-
jects and 70 hypertensive subjects. Bars
show meanSEM. *P0.05 compared
with AA/AG hypertensive subjects and
with AA/AG and GG normotensive sub-
jects. C, The expression of phagocytic
p22phox protein was adjusted for the
expression of the housekeeping gene
-actin. D, p22phox protein expression
was determined in samples from 70 nor-
motensive subjects and 70 hypertensive
subjects. Bars show meanSEM.
*P0.05 compared with AA/AG hyper-
tensive subjects and with AA/AG and GG
normotensive subjects.
TABLE 2. Clinical Characteristics of Hypertensive Subjects Classified According
to the 930A/G Polymorphism
Parameter AA/AG GG P
Gender, male/female 29/6 29/6 NS
Age, years 612 602 NS
Body mass index, kg/m2 29.40.8 29.70.9 NS
Smokers, n (%) 12 (34) 9 (26) NS
Diabetics, n (%) 5 (14) 3 (9) NS
Systolic blood pressure, mm Hg 1492 1473 NS
Diastolic blood pressure, mm Hg 902 912 NS
Mean arterial pressure, mm Hg 1102 1103 NS
Pulse pressure, mm Hg 573 573 NS
Glucose, mg/dL 1053 1074 NS
Total cholesterol, mg/dL 2306 2399 NS
HDL-cholesterol, mg/dL 502 513 NS
LDL-cholesterol, mg/dL 1585 1647 NS
Triglycerides, mg/dL 1049 12110 NS
Granulocytes, cells/mm3 4316247 4017287 NS
Lymphocytes, cells/mm3 1707144 1990164 NS
Monocytes, cells/mm3 29526 35351 NS
Medication
Angiotensin-converting enzyme inhibitor, n (%) 8 (23) 7 (20) NS
Angiotensin II type-1 receptor antagonist, n (%) 5 (14) 4 (11) NS
Other antihypertensives, n (%) 5 (14) 6 (17) NS
Statins, n (%) 6 (17) 8 (23) NS
NS indicates not significant.
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addition, NOx levels were lower in GG than in AA/AG hyperten-
sive subjects (4.20.3 mol/L versus 5.40.4 mol/L, P0.05)
(Figure 5). No differences in NOx levels were found between the
AA/AG and GG genotypes in normotensive subjects
(6.30.5 mol/L versus 6.20.4 mol/L, PNS).
Discussion
The main finding of the present study is that the 930A/G
polymorphism of the p22phox gene was associated with p22phox
expression and NADPH oxidase activity in phagocytic cells
from patients with essential hypertension. In particular, hy-
pertensive patients carrying the GG genotype exhibited
greater p22phox mRNA and protein levels and NADPH oxidase
activity than AA/AG hypertensive patients. These associa-
tions were not affected by other confounding variables that
are known to influence NADPH oxidase expression and
activity (ie, blood pressure, cholesterol, glucose).19–21 There-
fore, these findings suggest that the930A/G polymorphism is
functional in essential hypertension.
Whereas p22phox mRNA levels were increased in GG
hypertensive subjects compared with AA/AG hypertensive
subjects, no differences were found in this parameter between
the 2 subgroups within the normotensive group. In agreement
with this, we found increased luciferase activity driven by the
A-to-G substitution in hypertensive but not in normotensive
VSMCs. Collectively, these data suggest that the 930A/G
polymorphism may be functionally relevant in the control of
the p22phox gene expression only under hypertensive condi-
tions. Although the mechanisms that underlie this control
remain unclear, one possibility is that the presence of the G
allele modulates the transcription of the p22phox gene. In this
regard, an analysis of the promoter sequence shows that the
930 polymorphic site lies on a potential binding site for
C/EBP transcription factors. Furthermore, our results show-
ing a higher effect of C/EBP overexpression in the transcrip-
tional activity of the G rather than of the A allelic p22phox
promoter constructs, enable us to suggest the involvement of
C/EBPs in the hypertensive phenotype. Several findings
showing a relevant role of C/EBPs in hypertension support
this possibility. C/EBP expression is nearly absent in WKY
VSMCs, whereas it is abnormally increased in SHR
VSMCs.22 Changes in angiotensinogen mRNA expression
associated with the 217A/G polymorphism of this gene are
regulated by several members of the C/EBP family.23 Inflam-
matory cytokines upregulate C/EBP expression,24 and cyto-
kine levels have been reported to be increased in phagocytic
cells in hypertensive patients.25 Alternatively, the G allele
may be in linkage disequilibrium with other genetic variants
that influence the transcriptional activity. In this regard, we
have identified other polymorphisms in the p22phox promot-
er,26 although their implication in hypertension remains to be
established.
Figure 3. Reporter gene expression
assays with p22phox gene promoter allelic
constructs. Changes in luciferase levels
induced by the A-to-G substitution at the
930 polymorphic site were determined
in VSMCs from (A) SHR, (B) WKY rats,
and (C) the cell line A7r5. C1-A indicates
A allelic construct; C1-G, G allelic con-
struct. Bars show meanSEM from 4
separate experiments performed by trip-
licate. *P0.05 compared with C1-A in
hypertensive cells.
Figure 4. Effect of C/EBP cotransfec-
tion on luciferase levels of p22phox pro-
moter allelic constructs in A7r5 cells. A,
Bars show meanSEM from 4 separate
experiments performed in quintuplicate.
C1-A indicates A allelic construct; C1-G,
G allelic construct. *P0.05 compared
with C1-A and C1-G; †P0.05 com-
pared with C1-A cotransfected with
C/EBP. B, Western blot experiment
shows a positive immunodetection of
C/EBP protein in C/EBP-transfected
A7r5 cells. C indicates control A7r5 cells;
T, C/EBP-transfected A7r5 cells. An
arrowhead points to the expressed pro-
tein band (35 kDa).
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Recent studies support a role for p22phox overexpression in
hypertension.27 An increased p22phox mRNA expression lead-
ing to greater NAD(P)H oxidase activity accompanied by
diminished NO availability and endothelial dysfunction has
been reported in several models of hypertension.9–11 Further-
more, angiotensin II–induced generation of ROS by NADPH
oxidase is augmented in VSMCs from peripheral arteries of
hypertensive patients.12 Finally, enhanced NADPH oxidase–
dependent production of ROS in lymphoblasts from subjects
with hypertension is associated with a greater p22phox subunit
abundance, but not with changes in the other NADPH oxidase
subunits.28 Therefore, p22phox overexpression may be a critical
determinant of NADPH oxidase overactivity in GG hyper-
tensive subjects. Moreover, the higher O2 generation ob-
served in GG hypertensive subjects was associated with
diminished production of systemic NO. The potential rele-
vance of this finding is further supported by recent research
demonstrating that NADPH oxidase is involved in the uncou-
pling of the endothelial NO synthase, which favors a dimin-
ished NO generation in hypertensive animals.29 Nevertheless,
we cannot exclude the existence of oxidative stress in AA/AG
hypertensive subjects, which may be mediated by the trigger-
ing of other oxidative systems, including uncoupled endothe-
lial NO synthase and xanthine oxidase.3,30 In addition, oxi-
dative stress in hypertensive subjects may be also the
consequence of a decrease in the activity of antioxidant
mechanisms.31
Preactivated monocytes in hypertensive patients exhibit a
higher production of cytokines and a greater adherence to the
vascular wall25,32 and may play a key role in the oxidative
stress–mediated pathogenesis of atherosclerosis.33 Thus, our
data showing increased NADPH oxidase expression and
activity in phagocytic mononuclear cells, including mono-
cytes, from GG hypertensive patients suggest this genotype
may constitute an important proatherogenic feature in these
patients. This possibility is supported by findings demonstrat-
ing that the severity of atherosclerosis correlates with p22phox
mRNA overexpression34 and that p22phox mutations are able to
regulate NADPH oxidase activity in atherosclerosis.35 Fur-
ther clinical studies are necessary to ascertain whether the
930A/G polymorphism is actually involved in the develop-
ment of atherosclerosis in hypertensive patients.
Some limitations of the study should be acknowledged.
First, the study was performed in a small population, so we
are aware that additional studies, including larger numbers of
subjects, should be performed to confirm the current results.
Second, because PKC activity is upregulated in the vascula-
ture in hypertension,12,21 it may be suggested that the NADPH
oxidase–activity results in response to PMA, an agonist of
PKC, had been provoked by the use of this stimulus.
However, the values of NADPH oxidase activity in AA/AG
hypertensive subjects were almost identical to those mea-
sured in AA/AG normotensive subjects. Thus, we can discard
any significant contribution resulting from the stimulus used
on the increased NADPH oxidase activity observed in GG
hypertensive subjects. Third, although our findings show a
greater impact of GG genotype on p22phox protein abundance
than on p22phox mRNA levels in hypertensive subjects, it may
be suggested that genetically determined small changes in
p22phox mRNA levels may play a relevant role in the p22phox
protein expression. In accordance with this, it has been
reported that changes in p22phox phagocytic expression are
regulated by posttranscriptional mechanisms.36
Perspectives
The findings presented here suggest that the p22phox gene
930A/G polymorphism determines p22phox expression and
NADPH oxidase activity in phagocytic cells from patients
with essential hypertension. Increased NADPH oxidase O2
production might lead to a diminished NO production in GG
hypertensive patients. Therefore, the interaction between GG
genotype and factors linked to the hypertensive phenotype
may be involved in cardiovascular damage mediated by
NADPH oxidase–dependent oxidative stress in hypertensive
patients.
Acknowledgments
This project was funded through the agreement between Fundacio´n
para la Investigacio´n Me´dica Aplicada and Unio´n Temporal de
Empresas project Centro para la Investigacio´n Me´dica Aplicada, and
by grants 96/2000 from Department of Education and Culture,
55/2002 and 56/2002 from Department of Health of Government of
Navarra, and SAF2001–0914 from Ministry of Science and Tech-
nology, Spain. We gratefully acknowledge technical assistance by
Raquel Ros and Ana Montoya.
References
1. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature:
molecular and cellular mechanisms. Hypertension. 2003;42:1075–1081.
2. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and
the pathogenesis of atherosclerosis. Oxidative stress and the mediation of
arterial inflammatory response: a new perspective. Hypertension. 1995;
25:155–161.
3. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases:
the role of oxidant stress. Circ Res. 2000;87:840–844.
4. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular
system. Prog Cardiovasc Dis. 1995;38:87–104.
5. Mohazzab KM, Kaminski PM, Wolin MS. NADH oxidoreductase is a
major source of superoxide anion in bovine coronary artery endothelium.
Am J Physiol. 1994;266:H2568–H2572.
Figure 5. Association of the 930A/G polymorphism with NOx
levels. NOx levels were estimated by a colorimetric assay in
serum samples from 70 normotensive subjects and 70 hyper-
tensive subjects. Bars show meanSEM. *P0.05 compared
with AA/AG hypertensive subjects and with AA/AG and GG nor-
motensive subjects.
168 Hypertension August 2004
6. Pagano P, Ito Y, Tornheim K, Gallop P, Tauber A, Cohen R. An NADPH
oxidase superoxide-generating system in the rabbit aorta. Am J Physiol.
1995;268:H2274–H2280.
7. Rajagopalan S, Kurz S, Mu¨nzel T, Tarpey M, Freeman BA, Griendling
KK, Harrison DG. Angiotensin II-mediated hypertension in the rat
increases vascular superoxide production via membrane NADH/NADPH
oxidase activation: contribution to alterations of vasomotor tone. J Clin
Invest. 1996;97:1916–1923.
8. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK.
p22phox is a critical component of the superoxide-generating
NADH/NADPH oxidase system and regulates angiotensin II-induced
hypertrophy in vascular smooth muscle cells. J Biol Chem. 1996;271:
23317–23321.
9. Zalba G, Beaumont FJ, San Jose´ G, Fortun˜o A, Fortun˜o MA, Etayo JC,
Dı´ez J. Vascular NADH/NADPH oxidase is involved in enhanced
superoxide production in spontaneously hypertensive rats. Hypertension.
2000;35:1055–1061.
10. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q IV, Taylor
WR, Harrison DG, de Leon H, Wilcox JN, Griendling KK. P22phox
mRNA expression and NADPH oxidase activity are increased in aortas
from hypertensive rats. Circ Res. 1997;80:45–51.
11. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase
and enhanced superoxide production in the mineralocorticoid hyper-
tensive rat. Hypertension. 2001;38:1107–1111.
12. Touyz RM, Schiffrin EL. Increased generation of superoxide by angio-
tensin II in smooth muscle cells from resistance arteries of hypertensive
patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive
pathways. J Hypertens. 2001;19:1245–1254.
13. Dinauer MC, Pierce EA, Bruns GAP, Curnutte JT, Orkin SH. Human
neutrophil cytochrome b light chain (p22-phox). Gene structure, chro-
mosomal location, and mutations in cytochrome-negative autosomal
recessive chronic granulomatous disease. J Clin Invest. 1990;86:
1729–1737.
14. Cross AR, Noack D, Rae J, Heyworth PG. Hematologically important
mutations: the autosomal recessive forms of chronic granulomatous
disease. Blood Cells Mol Dis. 2000;26:561–565.
15. Zalba G, San Jose´ G, Beaumont FJ, Fortun˜o MA, Fortun˜o A, Dı´ez J.
Polymorphisms and promoter overactivity of the p22phox gene in vascular
smooth muscle cells from SHR. Circ Res. 2001;88:217–222.
16. Moreno MU, San Jose G, Orbe J, Paramo JA, Beloqui O, Dı´ez J, Zalba
G. Preliminary characterisation of the promoter of the human p22phox
gene: identification of a new polymorphism associated with hypertension.
FEBS Lett. 2003;542:27–31.
17. Tarpey MM, Fridovich I. Methods of detection of vascular reactive
species: nitric oxide, superoxide, hydrogen peroxide, and peroxynitrite.
Circ Res. 2001;89:224–236.
18. Rosselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating
nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted
with 17 beta-estradiol and norethisterone acetate. A two-year follow-up
study. Hypertension. 1995;25:848–853.
19. Rueckschloss U, Galle J, Holtz J, Zerkowski HR, Morawietz H. Induction
of NAD(P)H oxidase by oxidized low-density lipoprotein in human
endothelial cells: antioxidative potential of hydroxymethylglutaryl
coenzyme A reductase inhibitor therapy. Circulation. 2001;104:
1767–1772.
20. Lee HS, Son SM, Kim YK, Hong KW, Kim CD. NAD(P)H oxidase
participates in the signaling events in high glucose-induced proliferation
of vascular smooth muscle cells. Life Sci. 2003;72:2719–2730.
21. Ungvari Z, Csiszar A, Huang A, Kaminski PM, Wolin MS, Koller A.
High pressure induces superoxide production in isolated arteries via
protein kinase C-dependent activation of NAD(P)H oxidase. Circulation.
2003;108:1253–1258.
22. Kitami Y, Fukuoka T, Hiwada K, Inagami T. A high level of CCAAT-
enhancer binding protein-delta expression is a major determinant for
markedly elevated differential gene expression of the platelet-derived
growth factor-alpha receptor in vascular smooth muscle cells of genet-
ically hypertensive rats. Circ Res. 1999;84:64–73.
23. Jain S, Tang X, Narayanan CS, Agarwal Y, Peterson SM, Brown CD, Ott
J, Kumar A. Angiotensinogen gene polymorphism at 217 affects basal
promoter activity and is associated with hypertension in African-
Americans. J Biol Chem. 2002;277:36889–36896.
24. Poli V. The role of C/EBP isoforms in the control of inflammatory and
native immunity functions. J Biol Chem. 1998;273:29279–29282.
25. Do¨rffel Y, La¨tsch C, Stuhlmu¨ller B, Schreiber S, Scholze S, Burmester
GR, Scholze J. Preactivated peripheral blood monocytes in patients with
essential hypertension. Hypertension. 1999;34:113–117.
26. Moreno MU, San Jose´ G, Dı´ez J, Zalba G. Polymorphisms in the
promoter region of the human p22phox gene. Hypertension. 2001;38:979.
Abstract.
27. Zalba G, San Jose G, Moreno MU, Fortuno MA, Fortuno A, Beaumont
FJ, Dı´ez J. Oxidative stress in arterial hypertension: role of NAD(P)H
oxidase. Hypertension. 2001;38:1395–1399.
28. Pettit AI, Wong RKM, Lee V, Jennings S, Quinn PA, Ng LL. Increased
free radical production in hypertension due to increased expression of the
NADPH oxidase subunit p22phox in lymphoblast cell lines. J Hypertens.
2002;20:677–683.
29. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM,
Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to
uncoupling of endothelial cell nitric oxide synthase in hypertension.
J Clin Invest. 2003;111:1201–1209.
30. Suzuki H, Delano FA, Parks DA, Jamshidi N, Granger DN, Ishii H,
Suematsu M, Zweifac BW, Schmid-Schonbein GW. Xanthine oxidase
activity associated with arterial blood pressure in spontaneously hyper-
tensive rats. Proc Natl Acad Sci U S A. 1998;54:775–784.
31. Redo´n J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, Sa´ez GT.
Antioxidant activities and oxidative stress byproducts in human hyper-
tension. Hypertension. 2003;41:1096–1101.
32. Hilgers KF. Monocytes/macrophages in hypertension. J Hypertens. 2002;
20:593–596.
33. Dorffel Y, Franz S, Pruss A, Neumann G, Rohde W, Burmester GR,
Scholze J. Preactivated monocytes from hypertensive patients as a factor
for atherosclerosis?. Atherosclerosis. 2001;157:151–160.
34. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP,
Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling KK.
Superoxide production and expression of nox family proteins in human
atherosclerosis. Circulation. 2002;105:1429–1435.
35. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R,
Chanon KM. Functional effect of the C242T polymorphism in the
NAD(P)H oxidase p22phox gene on vascular superoxide production in
atherosclerosis. Circulation. 2000;102:1744–1747.
36. Dusi S, Donini M, Lisandrini D, Mazzi P, Della Bianca V, Rossi F.
Mechanisms of expression of NADPH oxidase components in human
cultured monocytes: role of cytokines and transcriptional regulators
involved. Eur J Immunol. 2001;31:929–938.
San Jose´ et al Functional Effect of p22phox 930A/G Polymorphism 169
